Corvus Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:CRVS) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Total assets 58.81 M68.91 M59.44 M89.46 M80.47 M Total liabilities 46.41 M36.34 M10.11 M9.23 M8.71 M Total equity 12.41 M32.57 M49.33 M80.23 M71.77 M Total liabilities & shareholders' equities 58.81 M68.91 M59.44 M89.46 M80.47 M Total debt ————— Net debt —————

뉴스

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 - Slideshow (NASDAQ:CRVS) 2026-01-27

Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know

Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet

Intel, Oracle among market cap stock movers on Monday

Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Ambitions Enterprise Mgmt (NASDAQ:AHMA), Argo Blockchain (NASDAQ:ARBK)

Apple, Microsoft, Meta To Report Results; Fed’s Interest Rate Decision In Focus

Corvus Pharmaceuticals, 공모로 2억 120만 달러 조달

Corvus Pharmaceuticals raises $201.2 million in upsized public offering

Cantor Fitzgerald, Corvus Pharmaceuticals 투자의견 ’비중확대’ 유지

Cantor Fitzgerald reiterates Overweight rating on Corvus Pharmaceuticals stock

제퍼리스, 강력한 AD 데이터에 코버스 파마슈티컬 목표 주가 $42로 상향